Human Monocolonal Antibodies for CNS Remyelination
Award last edited on: 4/2/21

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Eric W Chojnicki

Company Information

Acorda Therapeutics Inc

2 Blue Hill Plaza 3rd Floor
Pearl River, NY 10965
   (914) 347-4300

Research Institution

Mayo Foundation

Phase I

Contract Number: 1R41NS040172-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
The primary goal of this research is to develop a therapeutic approach to multiple sclerosis (MS) and other demyelinating conditions that uses naturally occurring autoantibodies directed against human oligodendrocytes to enhance remyelination. Promoting remyelination has the potential to protect vulnerable axons, increase axon conduction velocity, and improve neurologic deficits. Several polyreactive mouse IgM monoclonaI antibodies (mAbs) have been identified that recognize oligodendrocyte surface antigens and promote remyelination in mouse models of MS. More recently, utilizing an antigen4ridependent screening strategy, human mAbs have been identified, that bind to both rodent and human oligodendrocytes, and promote central nervous system (CNS) remyelination in mice. These results suggest that CNS antigen-specific antibodies that can enhance CNS repair are part of the normal immunoglobulin repertoire. Increasing the serum concentration of these CNS-reactive mAbs may help protect the CNS from pathogenic immune injury and promote myelin repair. Treatment with human remyelination- promoting mAbs may therefore be an effective and easily implemented therapy for human demyelinating conditions. The goal of this project is to develop a vector system for the high level expression of human IgM antibodies in transfected cells in culture and to use this system to produce human remyelination promoting antibodies for studies with the mouse models of demyelinating disease. The development of this system would represent a small scale model for the production of antibody for clinical trials in humans. Anti-idiotype antibodies will also be generated for use in the quantification and characterization of the remyelination promoting antibodies during production and as tools to monitor the antibodies during therapy. PROPOSED COMMERCIAL APPLICATION: The monoclonal antibodies (Mabs) to be developed in this grant have potential important applications as promoters of remyelination in the central nervous system Demyelinating conditions such as multiple sclerosis affect over half a million Americans and represent over $14 billion in annual costs to society in the U.S. alone. Currently available therapies for MS may slow progression of disease but do not repair existing demyelination of the CNS.

Thesaurus Terms:
biotechnology, immunologic preparation, monoclonal antibody, myelination, nervous system regeneration, technology /technique development autoantibody, immunoglobulin M, multiple sclerosis, transfection /expression vector laboratory mouse

Phase II

Contract Number: 2R42NS040172-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
(last award dollars: 2004)
Phase II Amount

The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such as MS. These antibodies, designated sHIgM22 and sHIgM46, were isolated by the Rodriquez laboratory at the Mayo Clinic by screening a bank of sera from patients with monoclonal gammopathy. The isolation, cloning and characterization of these antibodies were part of the specific aims of a Phase I STTR grant. The antibodies have been demonstrated to react with oligodendrocytes and to stimulate remyelination in the Theiler's Murine Encephalomyelitis Virus model in the SJL/J mouse. The specific aims of the current grant will be: Extend the characterization of each of these antibodies to the identification of the biologically relevant antigen and further elucidate the underlying mechanism by which the antibodies stimulate remyelination. Develop a robust scaleable manufacturing system that is suitable for producing commercial and clinical supplies of antibody. Extend the testing of the antibodies into other model systems of inflammatory CNS demyelinating disease and assess the toxicologic, pharmacokinetic and ADME properties of the antibodies.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Antigen Antibody Reaction, Biotechnology, Immunoglobulin M, Immunologic Substance Development /Preparation, Monoclonal Antibody, Myelination, Nervous System Regeneration Autoantibody, Gammopathy, Multiple Sclerosis, Oligodendroglia, Pharmacokinetics Epitope Mapping, Laboratory Mouse, Protein Purification